SPRINT® MicroLead
FDA Clears SPR Therapeutics’ Non-opioid SPRINT endura and extensa Peripheral Nerve Stimulation Systems for Pain Management
August 16, 2018 08:30 ET | SPR Therapeutics, Inc.
SPRINT® is the First and Only Dual Lead Capable PNS Platform Company also provides first look at 12-month durability outcomes following 60-day SPRINT therapy CLEVELAND, Aug. 16, 2018 (GLOBE...
Helius Medical Technologies Announces Positive Results from its Registrational Clinical Trial for Traumatic Brain Injury (TBI)
November 09, 2017 06:00 ET | Helius Medical Technologies, Inc.
NEWTOWN, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX:HSM) (OTCQB:HSDT) ("Helius" or the "Company"), a medical technology company focused on neurological wellness,...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics® Secures $25 Million in Series C Financing
September 12, 2017 08:03 ET | SPR Therapeutics, LLC
CLEVELAND, Sept. 12, 2017 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., (SPR) a private medical device company that has developed a novel neurostimulation technology for chronic and acute pain,...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Promotes Dr. Joseph Boggs to SVP of Research and Development
September 07, 2017 09:13 ET | SPR Therapeutics, LLC
CLEVELAND, Sept. 07, 2017 (GLOBE NEWSWIRE) -- SPR® Therapeutics, LLC (SPR), a private medical device company that has developed a novel, evidence-based neurostimulation platform for chronic and...
SPR Therapeutics LOGO 361 TM.jpg
Opioid Concerns and Work Interference Cited as Top Reasons to Delay Knee Replacement Surgery
August 03, 2017 11:03 ET | SPR Therapeutics, LLC
CLEVELAND, Ohio, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Patients in need of a total knee replacement (TKR) often delay surgery by two or more years because of concerns about the duration of postoperative...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Awarded $6M Contract From the United States Department of Defense to Advance Non-Opioid Pain Relief Therapy
May 15, 2017 09:03 ET | SPR Therapeutics, LLC
CLEVELAND, May 15, 2017 (GLOBE NEWSWIRE) -- SPR Therapeutics (SPR) has been awarded a $6M four-year contract from the U.S. Department of Defense (DoD) to further advance its SPRINT™ Peripheral Nerve...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Appoints Michael P. Chuisano to Board of Directors
March 21, 2017 09:33 ET | SPR Therapeutics, LLC
CLEVELAND, March 21, 2017 (GLOBE NEWSWIRE) -- SPR Therapeutics, LLC, a private medical device company that has developed a novel, evidence-based neurostimulation platform for chronic and acute pain,...
SPR Therapeutics LOGO 361 TM.jpg
Les C. Vinney Named 2016 NACD Top 100 Directors
January 19, 2017 09:30 ET | SPR Therapeutics, LLC
CLEVELAND, Jan. 19, 2017 (GLOBE NEWSWIRE) -- The National Association of Corporate Directors (NACD) has named SPR® Therapeutics’ Board Member, Les C. Vinney, one of the top 100 most influential...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Names Dave Youngberg Vice President of Sales
January 17, 2017 09:30 ET | SPR Therapeutics, LLC
CLEVELAND, Jan. 17, 2017 (GLOBE NEWSWIRE) -- SPR® Therapeutics announced today that industry veteran, Dave Youngberg, has joined the neurostimulation company as Vice President of Sales. ...
22157.jpg
Global Neurostimulation Devices Market 2012-2016 Report with Medtronic Inc., St. Jude Medical Inc., Boston Scientific Corp., Dominating
October 30, 2013 12:56 ET | Research and Markets
Dublin, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/rqc6pg/global) has announced the addition of the "Global Neurostimulation Devices Market...